Description
MK-0752 is an investigational medication currently being studied by Merck Sharp & Dohme LLC. It is being evaluated in clinical trials, including one specifically for patients with advanced colorectal cancer. This trial (NCT01243762) is a Phase 1 study, meaning it primarily focuses on determining the safety and tolerability of MK-0752, often in combination with other drugs. In this specific trial, MK-0752 is being combined with dalotuzumab and tested in patients with advanced colorectal cancer. The trial is designed to find the highest safe dose of the combination and to look for early signs of anti-tumor activity. The trial arm using MK-0752 is specifically enrolling patients with metastatic or recurrent colorectal cancer who have a specific genetic characteristic known as wild-type KRAS. MK-0752 is not yet approved for use in colorectal cancer or any other condition.
Mechanism of Action
MK-0752 is being investigated as part of a combination therapy. The specific mechanism of action of MK-0752 is being studied in clinical trials. It is being combined with dalotuzumab, which targets a protein called DLL4, and other investigational agents like MK-2206 and ridaforolimus. The goal of these combinations is to target multiple pathways involved in cancer growth and survival. The specific molecular target or pathway affected by MK-0752 is not fully characterized in publicly available information, but it is being investigated in the context of KRAS wild-type colorectal cancer.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.